1. Biomarkers for Cancer Immunotherapy: Understanding Their Growing Role in Pan Tumors

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. What Is a Biomarker?

4. Categories of Biomarkers

5. What Do We Look for in a Biomarker?

6. Predictive Factors

7. The 3 Phases of Cancer Immunoediting

8. FDA-Approved Immune Checkpoint Inhibitors: Ipilimumab

9. FDA-Approved Immune Checkpoint Inhibitors: Nivolumab

10. FDA-Approved Immune Checkpoint Inhibitors: Pembrolizumab

11. FDA-Approved Immune Checkpoint Inhibitors: Atezolizumab

12. The Blueprint PD-L1 IHC Assay Comparison Project

13. The Blueprint PD-L1 IHC Assay Comparison Project (cont)

14. What Is Needed?

15. KEYNOTE 024 First-Line Setting: Pembrolizumab vs Platinum Doublets

16. First-Line Pembrolizumab: 024 PFS

17. First-Line Pembrolizumab: 024 OS

18. Implications for Practice

19. KEYNOTE-021 Phase 2 Trial

20. PD-L1 Blockade in Colorectal Cancer

21. MSI-High CRC: Nivolumab Monotherapy

22. KEYNOTE-028 for PD-L1+ CRC

23. Mutation Load and Neoantigens

24. ONO 12 (ATTRACTION-2) Phase 3 Study

25. ONO 12 (ATTRACTION-2) Phase 3 Study (cont)

26. Cancer Immunotherapy: Multiple Drugs in Development

27. Examples of Investigational Immune Checkpoint Inhibitors Solid Tumors

28. Concluding Remarks